A study comparing gemcitibine and carboplatin with or without LY2228820 for women with ovarian cancer

Mise à jour : Il y a 5 ans
Référence : EUCTR2011-005197-40

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase 1b - to determine the recommended Phase 2 dose of LY2228820 that can be safely administered with gemcitabine and carboplatin Phase 2 - to compare the progression-free survival in patients treated with LY2228820 plus gemcitabine and carboplatin versus placebo plus gemcitabine and carboplatin


Critère d'inclusion

  • Epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer